Drugs Made In Key Fundamental Indicators
| DMII Stock | 9.98 0.03 0.30% |
As of the 3rd of March, Drugs Made shows the Mean Deviation of 0.0982, standard deviation of 0.1474, and Coefficient Of Variation of 857.92. Drugs Made In technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Drugs Made's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Drugs Made's valuation are provided below:Drugs Made In does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drugs Fundamental Market Drivers
| Short Percent Float | 0.0014 | |
| Shares Short Prior Month | 86 K | |
| Short Percent | 0.0014 |
Drugs Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Drugs Made is extremely important. It helps to project a fair market value of Drugs Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Drugs Made's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Drugs Made's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Drugs Made's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Drugs Made 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Drugs Made's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Drugs Made.
| 12/03/2025 |
| 03/03/2026 |
If you would invest 0.00 in Drugs Made on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Drugs Made In or generate 0.0% return on investment in Drugs Made over 90 days. Drugs Made is related to or competes with Jackson Acquisition, Launch One, Oxley Bridge, and Graf Global. Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. More
Drugs Made Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Drugs Made's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Drugs Made In upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 0.1929 | |||
| Information Ratio | (0.43) | |||
| Maximum Drawdown | 0.9098 | |||
| Value At Risk | (0.30) | |||
| Potential Upside | 0.3036 |
Drugs Made Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drugs Made's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Drugs Made's standard deviation. In reality, there are many statistical measures that can use Drugs Made historical prices to predict the future Drugs Made's volatility.| Risk Adjusted Performance | 0.0472 | |||
| Jensen Alpha | 0.0063 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | (0.33) | |||
| Treynor Ratio | 0.5883 |
Drugs Made March 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0472 | |||
| Market Risk Adjusted Performance | 0.5983 | |||
| Mean Deviation | 0.0982 | |||
| Downside Deviation | 0.1929 | |||
| Coefficient Of Variation | 857.92 | |||
| Standard Deviation | 0.1474 | |||
| Variance | 0.0217 | |||
| Information Ratio | (0.43) | |||
| Jensen Alpha | 0.0063 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | (0.33) | |||
| Treynor Ratio | 0.5883 | |||
| Maximum Drawdown | 0.9098 | |||
| Value At Risk | (0.30) | |||
| Potential Upside | 0.3036 | |||
| Downside Variance | 0.0372 | |||
| Semi Variance | (0.01) | |||
| Expected Short fall | (0.17) | |||
| Skewness | 0.3601 | |||
| Kurtosis | 2.78 |
Drugs Made In Backtested Returns
Drugs Made is very steady at the moment. Drugs Made In secures Sharpe Ratio (or Efficiency) of 0.12, which denotes the company had a 0.12 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Drugs Made In, which you can use to evaluate the volatility of the firm. Please confirm Drugs Made's Mean Deviation of 0.0982, standard deviation of 0.1474, and Coefficient Of Variation of 857.92 to check if the risk estimate we provide is consistent with the expected return of 0.0169%. Drugs Made has a performance score of 9 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0122, which means not very significant fluctuations relative to the market. As returns on the market increase, Drugs Made's returns are expected to increase less than the market. However, during the bear market, the loss of holding Drugs Made is expected to be smaller as well. Drugs Made In right now shows a risk of 0.15%. Please confirm Drugs Made In expected short fall, and the relationship between the value at risk and daily balance of power , to decide if Drugs Made In will be following its price patterns.
Auto-correlation | 0.39 |
Below average predictability
Drugs Made In has below average predictability. Overlapping area represents the amount of predictability between Drugs Made time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Drugs Made In price movement. The serial correlation of 0.39 indicates that just about 39.0% of current Drugs Made price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | 0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 53% of Drugs Made In are shares owned by institutions. This is 81.37% higher than that of the Capital Markets sector and significantly higher than that of the Financials industry. The shares owned by institutions for all United States stocks is 37.57% lower than that of the firm.
Drugs Made In Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Drugs Made's current stock value. Our valuation model uses many indicators to compare Drugs Made value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Drugs Made competition to find correlations between indicators driving Drugs Made's intrinsic value. More Info.Drugs Made In is rated as one of the top companies in current valuation category among its peers. It also is one of the top stocks in shares outstanding category among its peers creating about 0.10 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Drugs Made In is roughly 9.98 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Drugs Made's earnings, one of the primary drivers of an investment's value.Drugs Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Drugs Made's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Drugs Made could also be used in its relative valuation, which is a method of valuing Drugs Made by comparing valuation metrics of similar companies.Drugs Made is currently under evaluation in shares owned by institutions category among its peers.
Drugs Fundamentals
| Current Valuation | 654.73 M | ||||
| Shares Outstanding | 65.58 M | ||||
| Shares Owned By Insiders | 17.63 % | ||||
| Shares Owned By Institutions | 53.94 % | ||||
| Number Of Shares Shorted | 83.8 K | ||||
| Book Value Per Share | (0.26) X | ||||
| Short Ratio | 0.96 X | ||||
| Market Capitalization | 654.44 M |
About Drugs Made Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Drugs Made In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Drugs Made using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Drugs Made In based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.